Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying

Rugmani Padmanabhan Iyer1, Lisandra E de Castro Brás2, Nicolle L Patterson3

  • 1San Antonio Cardiovascular Proteomics Center, USA; Mississippi Center for Heart Research, Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA.

Insights

Early inhibition of matrix metalloproteinase-9 (MMP-9) after myocardial infarction (MI) in mice unexpectedly worsened cardiac function by delaying inflammation resolution and increasing inflammatory cell infiltration. Targeting MMP-9 early post-MI is not a viable therapeutic strategy.

Area of Science:

  • Cardiovascular Research
  • Inflammation and Immunology
  • Drug Discovery and Development

Background:

  • Matrix metalloproteinase-9 (MMP-9) is elevated post-myocardial infarction (MI) and its genetic deletion improves cardiac remodeling.
  • Targeted MMP-9 inhibition is explored as a therapeutic strategy to attenuate cardiac dysfunction post-MI.

Purpose of the Study:

  • To determine if selective MMP-9 inhibition early post-MI is an effective therapeutic strategy in a mouse model.
  • To investigate the effects of MMP-9 inhibition on cardiac remodeling, inflammation, and cardiac function post-MI.

Main Methods:

  • Male C57BL/6J mice underwent coronary artery ligation to induce MI.
  • Mice were treated with saline or an MMP-9 inhibitor (MMP-9i) starting 3 hours post-MI.
  • Cardiac function, infarct area, inflammatory cell infiltration, apoptosis, and cytokine expression were assessed at Day 1 and Day 7 post-MI.

Main Results:

  • MMP-9i reduced MMP-9 activity but did not affect survival or infarct size.
  • MMP-9i treatment worsened cardiac function and increased infarct wall thinning by Day 7 post-MI.
  • MMP-9i enhanced neutrophil and macrophage infiltration, prolonged inflammation, reduced apoptosis, and altered baseline plasma proteomes.

Conclusions:

  • Early MMP-9 inhibition post-MI delayed inflammation resolution and exacerbated cardiac dysfunction in mice.
  • The findings highlight potential differences between genetic deletion and pharmacological inhibition of MMP-9.
  • Translational approaches are crucial for evaluating therapeutic strategies in the context of complex biological responses.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
296
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
529
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
376